Welcome to our dedicated page for Capricor Therapeutics SEC filings (Ticker: CAPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Capricor Therapeutics filings document a Delaware biotechnology issuer developing cell and exosome-based therapeutics, including Deramiocel for Duchenne muscular dystrophy. Its 8-K reports record quarterly and annual financial results, FDA communications tied to the Deramiocel Biologics License Application, Regulation FD disclosures, and material-event reporting for litigation-related actions.
Proxy materials address board elections, executive compensation, equity awards, shareholder voting matters, and other governance disclosures. The filing record also identifies CAPR common stock, par value $0.001 per share, as a Nasdaq-listed security and provides formal disclosure around operating results, capital structure, and public-company status.
CAPRICOR THERAPEUTICS Chief Financial Officer Anthony Bergmann exercised stock options to acquire 3,000 shares of common stock at an exercise price of $1.39 per share. These options came from a 2016 grant that was adjusted for a 1-for-10 reverse stock split and a later share reprice. Following the exercise, Bergmann directly holds 11,223 common shares. The option grant vested in equal monthly installments over 48 months beginning July 1, 2016.
CAPR amendment to Form 144/A reports an affiliate sale of 10,000 shares of Common Stock tied to a stock award granted 06/22/2022. The filing shows a reported gross value of $273,200.00 and lists Fidelity Brokerage Services LLC as the broker on 05/19/2026.
This filing amends prior Form 144 details and documents the transaction type as Compensation (stock award). The disclosure lists the exchange as NASDAQ and identifies the securities class as Common Stock.
Filer submitted a Form 144 notification referencing recent transactions in Common stock of CAPR. The listing shows multiple purchases and issuer stock awards on specific dates, including a 34,000-share award on 08/07/2024 and a 16,156-share award on 04/23/2024.
The entry list also includes open-market purchases such as 5,083 shares on 10/09/2023 and 2,500 shares on 10/04/2023. The filing presents transaction types and dates but does not itemize sales during the past three months in the provided excerpt.
Capricor Therapeutics director Frank Litvack reported a routine option exercise. He exercised stock options covering 3,937 shares of Common Stock at $1.39 per share, converting a derivative position into direct share ownership. Following the exercise, he holds 133,776 Common shares directly and 46,278 Common shares indirectly through the Litvack Curtis Family Trust, where he serves as trustee. The exercised option grant, originally issued in 2016, had been adjusted for a 1-for-10 reverse stock split in 2019 and a share reprice in 2020. No open-market purchases or sales were reported in this filing.
Capricor Therapeutics reported first quarter 2026 results with a net loss of $33.9 million, compared with $24.4 million a year earlier, as it continues late-stage development of Deramiocel for Duchenne muscular dystrophy. Revenue was $0 for both periods, reflecting the company’s pre-commercial stage.
Research and development expenses increased to $27.4 million from $18.9 million, while general and administrative costs rose to $9.4 million from $6.1 million. Investment income grew to $2.9 million, partially offsetting operating losses. Cash, cash equivalents and marketable securities totaled $278.6 million as of March 31, 2026, down from $318.1 million at December 31, 2025.
Management highlighted ongoing FDA review of its Biologics License Application for Deramiocel, with a PDUFA target action date of August 22, 2026, and noted recent legal action involving NS Pharma related to commercialization arrangements and patient access.
CAPRICOR THERAPEUTICS, INC. EVP and general counsel Karen Krasney reported an exercise-and-sell transaction in the company’s common stock. She sold 25,000 shares in an open-market sale on May 1, 2026 at a weighted average price of $31.7019 per share, under a pre-arranged Rule 10b5-1 trading plan.
On the same date, she exercised stock options to acquire 25,000 shares of common stock at an exercise price of $3.18 per share. Following these transactions, she directly holds 30,547 shares of Capricor common stock.
Capricor Therapeutics chief financial officer Anthony Bergmann executed a combined option exercise and share sale involving 25,000 shares of common stock. He exercised stock options to acquire 25,000 shares at $3.18 per share, then sold 25,000 shares in an open‑market transaction at a weighted average price of $31.7016 per share.
The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted in December 2025, meaning the trades were scheduled in advance. After these transactions, Bergmann holds 8,223 shares of common stock directly and 116,980 stock options with a $3.18 exercise price expiring in 2032.